⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Chemotherapy Induced Peripheral Neuropathy (CIPN) Treatment Market Report 2026-2032: Revenues to Grow by $750M at 8.64% CAGR
globenewswire.com
ABBV
AMGN
PFE
BMY
MRK
REGN
SNY
TAK
NVS
GSK
HRTX
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
globenewswire.com
NVS
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More
globenewswire.com
GILD
NVS
BMY
ORGN
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
businesswire.com
NVS
BMY
AMGN
ZERO Prostate Cancer Announces 2026 Prostate Cancer Summit and Veterans Action Convening to Improve Care and Outcomes for Veterans
prnewswire.com
PFE
NVS
AZN
Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030 - Novartis' Pluvicto and Lutathera Have Catalyzed Commercial Momentum
globenewswire.com
NVS
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
accessnewswire.com
BDRX
GSK
PFE
NVS
COGT
AAV for the Hereditary Retinal Diseases Competitive Landscape Report 2026: Comprehensive Insights About 75+ Companies and 80+ Drugs
globenewswire.com
NVS
JNJ
FDMT
Monoclonal Antibodies Competitive Landscape Report 2026: Comprehensive Insights About 180+ Companies and 230+ Drugs by Company, Product, Stage of Development, Route of Administration, Molecule Type
globenewswire.com
BMY
GSK
NVS
NVO
Sickle Cell Disease Competitive Landscape Report 2026: Comprehensive Analysis of Over 40 Companies and More Than 50 Drugs
globenewswire.com
NVS
PFE
AGIO
CRSP
TAK